A VALIDATED STABILITY-INDICATING REVERSE-PHASE HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY METHOD FOR DACLATASVIR, IDENTIFICATION AND CHARACTERIZATION OF DEGRADATION PRODUCTS USING LC-ESI-QTOF-MS
Objective: The objective of this study was to report the stability of antiviral drug, daclatasvir (DCV) based on the information obtained from forced degradation studies and characterization of degradation products (DPs) by tandem mass spectrometry (MS/MS) analysis.
Methods: Chromatographic separation was achieved on Shimadzu liquid chromatography (LC) 20 AD high-performance LC system with photodiode array detector having Kromasil C18 (250 mm×4.6 mm×5 μm) with isocratic elution of a mobile phase composed of ammonium acetate buffer (pH 4.5) and acetonitrile in a ratio of 50:50 at 315 nm. The drug was subjected to forced hydrolytic, oxidative, photolytic, and thermal stress in accordance with the ICH guideline Q1A (R2). The drug showed degradation under acidic and basic hydrolytic conditions by forming two DPs. The DPs were characterized using LC– MS/MS studies and the pathways of fragmentation are proposed. Validation of the developed method was carried out in accordance with ICH guidelines.
Results: Two DPs were identified, DP-1 as (S)-1-((S)-2-(5-(4’-(2-((S)-1-((S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)pyrrolidin-2-yl)-1H-imidazol-5-yl)-[1,1’-biphenyl]-4-yl)-1H-imidazol-2-yl)pyrrolidin-1-yl)-3-methyl-1-oxobutan-2-aminium and DP-2 as (S)-2-(5-(4’-(2-((S)-1-((S)-2- ((methoxycarbonyl)amino)-3-methylbutanoyl)pyrrolidin-2-yl)-1H-imidazol-5-yl)-[1,1’-biphenyl]-4-yl)-1H-imidazol-2-yl)pyrrolidin-1-ium.
Conclusion: The method proved to be simple, accurate, precise, specific, robust, and less time consuming and can be applied for the determination of DCV in bulk and marketed formulation.
2. International Conference on Harmonization: (ICH): Q1A (R2), Stability Testing of New Drug Substances and Products: IFPMA; 2003.
3. International Conference on Harmonization: (ICH): Q3A (R2), Impurities in New Drug; 2006.
4. Bakshi M, Singh S. Development of validated stability-indicating assay methods-critical review. J Pharm Biomed Anal 2002;28:1011-40.
5. Sawant S, Barge V. A validated stability indicating RP-HPLC method for satranidazole, identification and characterization of a photolytic degradation product of satranidazole using LC-APCI-ION TRAP-MS. Int J Pharm Pharm Sci 2014;6:621-5.
6. Smith MA, Regal RE, Mohammad RA. Daclatasvir: A NS5A replication complex inhibitor for hepatitis C infection. Ann Pharmacother 2016;50:39-46.
7. Chakravarthy VA, Sailaja BB. Method development and validation of assay and dissolution methods for the estimation of daclatasvir in tablet dosage forms by reverse phase HPLC. Eur J Pharm Med Res 2016;3:356-64.
8. Saleh H, Ragab GH, Othman MA. Stability indicating HPLC method development and validation for determination of daclatasvir in pure and tablets dosage forms. Indo Am J Pharm Sci 2017;3:1565-72.
9. Baker MM, El-Kafrawy DS, Mahrous MS, Belal TS. Validated stability-indicating HPLC-DAD method for determination of the recently approved hepatitis C antiviral agent daclatasvir. Ann Pharm Fr 2017;75:176-84.
10. Hassib ST, Taha EA, Elkady EF, Barakat GH. Reversed-phase liquid chromatographic method for determination of daclatasvir dihydrochloride and study of its degradation behavior. Chromatographia 2017;80:1101-7.
11. Zaman B, Hassan W. Development of stability indicating HPLC-UV method for determination of daclatasvir and characterization of forced degradation products. Chromatographia 2018;81:785-97.
12. International Conference on Harmonization: ICH: Q2 (R1), Validation of Analytical Procedures: Text and Methodology; 1995.
13. International Conference on Harmonization ICH: Q2B, Analytical Validation-Methodology; 1996. p. 24.
14. International Conference on Harmonization ICH: Q2A, Text on Validation of Analytical Procedure; 1994. p. 22.
This work is licensed under a Creative Commons Attribution 4.0 International License.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.